---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007153"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T04:59:02.259672+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Q3 net loss $20.3M; Phase 3 Alzheimer's trial enrollment tops 650

## Summary
- Net loss $20.3M ($0.51/share) vs $9.6M loss in Q3 2021; R&D expenses rose to $18.5M.
- Cash and equivalents $174.7M with no debt; FY 2022 cash burn guidance $80-90M.
- Over 650 patients now enrolled in simufilam Phase 3 studies, up from 150 six months ago.
- Open-label study results expected year-end 2022; Cognition Maintenance Study results Q3 2023.

## SEC filing metadata
- accession: 0001171843-22-007153
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/f8k_110422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007153
- JSON: https://secwatch.observer/filing/0001171843-22-007153.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007153.txt

## Key facts
- Earnings Releases
  FILANA THERAPEUTICS, INC. updated its full-year 2022 guidance (reaffirmed).
  - Period: full-year 2022
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Net cash use for operations for full-year 2022 is expected to be approximately $80 to $90 million, consistent with previous guidance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm
- Earnings Releases
  FILANA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: net income $20.3 million, or $0.51 per share, EPS $0.51 per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: $20.3 million, or $0.51 per share
  - EPS: $0.51 per share
  - Result: reported results
  source text: Net loss for third quarter 2022 was $20.3 million, or $0.51 per share, compared to a net loss of $9.6 million, or $0.24 per share, for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184322007153/0001171843-22-007153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.